<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972426</url>
  </required_header>
  <id_info>
    <org_study_id>001-TWB-0901(n)</org_study_id>
    <nct_id>NCT00972426</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients</brief_title>
  <official_title>A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Otsuka Pharm. Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Otsuka Pharm. Co., Ltd</source>
  <brief_summary>
    <textblock>
      The primary objective of the clinical study is to evaluate the efficacy and safety for&#xD;
      Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change value of Intra-Ocular Pressure (IOP) in study group</measure>
    <time_frame>assessment will be done every month for 2 months for each subject</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change value of IOP between groups</measure>
    <time_frame>assessment will be done every month for 2 months for each subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change percentage of IOP in each group</measure>
    <time_frame>assessment will be done every month for 2 months for each subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of score of Patient satisfaction in each group</measure>
    <time_frame>assessment will be done every month for 2 months for each subject</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Treatment A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mikelan LA + Xalatan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timoptol XE + Xalatan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)</intervention_name>
    <description>Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks</description>
    <arm_group_label>Treatment A Group</arm_group_label>
    <arm_group_label>Treatment B Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females outpatients with primary open-angle glaucoma or ocular hypertension;&#xD;
&#xD;
          2. Subjects who have received Latanoprost at least 4 weeks, and in the end of screening&#xD;
             period, subject's Intra-Ocular Pressure is ≧18mmHg (choice of one eyes is possible),&#xD;
             or Investigator judges the reduction of IOP is insufficient of individual subject.&#xD;
&#xD;
          3. Aged between ≧ 20 and ≦80 years old when giving informed consent to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to either oral or topical beta-blocker therapy or to any ophthalmic&#xD;
             solution used in the study;&#xD;
&#xD;
          2. Patients wearing contact lenses;&#xD;
&#xD;
          3. Patients with severe dry eyes;&#xD;
&#xD;
          4. Patients who had ophthalmic surgery including cataract surgery, trabeculotomy or&#xD;
             trabeculectomy within three months of study start;&#xD;
&#xD;
          5. Patients who had laser trabeculoplasty within 2 months before starting study;&#xD;
&#xD;
          6. Patients who had corneal contamination, and acute ophthalmic infection, or&#xD;
             inflammatory ophthalmic disorder 2 months before starting study;&#xD;
&#xD;
          7. Patients who had herpetic keratitis or corneal ulcer within 2 months before starting&#xD;
             study;&#xD;
&#xD;
          8. Patient who are receiving systemic administration of drugs that may have and effect on&#xD;
             IOP;&#xD;
&#xD;
          9. Patients who have poorly controlled heart failure, sinus bradycardia, atrioventricular&#xD;
             block (1 and 2 grade), or cardiogenic shock;&#xD;
&#xD;
         10. Patients with brochial asthma, bronchospasm or severe chronic obstructive pulmonary&#xD;
             disease or a history thereof;&#xD;
&#xD;
         11. Patients with poorly controlled diabetes or diabetic ketoacidosis or metabolic&#xD;
             acidosis;&#xD;
&#xD;
         12. Patients with aortic stenosis, Raynaud's syndrome, intermittent claudication, or&#xD;
             pheochromocytoma;&#xD;
&#xD;
         13. Patients with myasthenia gravis;&#xD;
&#xD;
         14. Patients with severe hepatic or renal disorder judged by investigator;&#xD;
&#xD;
         15. Patients who have confirmed or potential pregnancy, current lactation, or wish to&#xD;
             become pregnant during the study period;&#xD;
&#xD;
         16. Patients who have treatment with any investigational drug when giving informed&#xD;
             consent;&#xD;
&#xD;
         17. Patients with significant alcohol, drug or medication abuse as judged by investigator;&#xD;
&#xD;
         18. Patients whom investigator judges as subjects to be inappropriate for the clinical&#xD;
             study (e.g., patient with severe complication)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Da-Wen Lu, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Opthalmology/ Tri-Service General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>September 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2009</study_first_posted>
  <last_update_submitted>September 1, 2011</last_update_submitted>
  <last_update_submitted_qc>September 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Carteolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

